• AFT Pharmaceuticals are a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over-the-counter, prescription and hospital.

    AFT's product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs.

  • Maxigesic global growth continues

    AFT Pharmaceuticals reported a strong lift in revenue and earnings for the 2020 financial year following sales growth and cost control in its diversified Australasian medicines business and growing international sales of its patented Maxigesic pain relief drug.

    To view the announcement please click here.

  • NZX

    Shares in AFT Pharmaceuticals Limited (“AFT”), began trading on the NZX Main Board and ASX on 22 December 2015, following the successful IPO that raised $35.6 million through the issue and sale of New and existing shares.

    To view the announcements please click here.

Latest Annual Meetings

2015

Date

Thursday 17 September 2015, 11:00am

Location Level 1, 129 Hurstmere Road,
Takapuna,
Auckland, 0622
New Zealand